Literature DB >> 17827841

Two cases of refractory post-bulbar duodenal ulcer.

Tateki Yamane1, Kan Uchiyama, Takayuki Ishii, Mitsuhiro Omura, Kiyotaka Fujise, Hisao Tajiri.   

Abstract

Two young man patients with refractory post-bulbar duodenal ulcer (post-bulbar ulcer) were encountered. They had a single punched-out ulcer in the absence of an underlying disease. Patient 1 was Helicobacter pylori (Hp)-positive, and did not respond to Hp eradication therapy. The ulcer scarred after the long-term administration of a proton pump inhibitor (PPI), but recurred after a reduction in the dose. Patient 2 was Hp-negative. His ulcer did not scar even after long-term PPI administration, but it formed a fistula into the gallbladder, and the fistula was surgically closed. In both patients, laboratory and imaging studies excluded Zollinger-Ellison syndrome, but suggested a hyperacidic tendency. Unlike duodenal bulb ulcer (bulbar ulcer), the post-bulbar ulcer in Patient 1 did not heal with Hp eradication therapy, suggesting that post-bulbar ulcer differs etiologically from bulbar ulcer. We speculate that the possible causes of the refractoriness to treatment in both patients were ulcer penetration, callosity formation, and insufficient inhibition of gastric acid secretion due to the impaired passage of PPI into the deep portion of the duodenum as a result of luminal narrowing.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17827841     DOI: 10.2169/internalmedicine.46.0113

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  2 in total

1.  Post-bulbar duodenal ulcer with anterior perforation with kissing ulcer and duodenocaval fistula: A case report and review of literature.

Authors:  Nasser Alzerwi
Journal:  World J Clin Cases       Date:  2022-09-06       Impact factor: 1.534

2.  Amelioration of alcohol‑induced gastric mucosa damage by oral administration of food‑polydeoxyribonucleotides.

Authors:  Jonghwan Kim; Soyoung Chun; Seul-Ong Ohk; Sanghoon Kim; Juwan Kim; Sungoh Lee; Hangyu Kim; Sujong Kim
Journal:  Mol Med Rep       Date:  2021-09-10       Impact factor: 2.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.